Immunology
Page 1 • 7 itemsGain critical insights into global immunology drug development, market trends, and regulatory landscapes. Inform your pharma BD and investment strategy.
UCB Acquires Candid Therapeutics for $2.2 Billion, Expanding T-Cell Engager Platform for Autoimmune Diseases
UCB's $2.2B acquisition of Candid Therapeutics brings novel T-cell engager technology for autoimmune diseases, marking major expansion beyond oncology applications.
Kodiak Sciences KSI-101 Clinical Data to Be Presented at Scientific Conferences for Macular Edema Treatment
Kodiak Sciences will present KSI-101 clinical data for macular edema secondary to inflammation, with Phase 3 results expected in Q4 2026.
Vivacta Bio Raises $50M+ Series A Funding for GT801 CAR-T Gene Therapy Development
Vivacta Biotechnology closes $50M+ Series A funding to advance GT801, an innovative in vivo CAR-T therapy for blood cancers and autoimmune diseases.
Samsung Bioepis Begins Phase 1 Trial for Novel ADC SBE303, Expands Sandoz Biosimilar Partnership
Samsung Bioepis launches first-in-human trial for ADC candidate SBE303 and expands Sandoz partnership for five biosimilars including vedolizumab.
Biogen Acquires Felzartamab Rights from TJ Biopharma for Greater China Market
Biogen consolidates global felzartamab rights through strategic acquisition from TJ Biopharma, expanding CD38-directed antibody reach in China market.
Zai Lab's ZL-1503 Bispecific Antibody Shows Promise for Rapid Itch Relief in Atopic Diseases
Zai Lab's ZL-1503, an IL-13/IL-31Rα bispecific antibody, demonstrates rapid itch relief and inflammation reduction in preclinical atopic disease studies.
Zai Lab's ZL-1503 Bispecific Antibody Shows Rapid Itch Relief in Atopic Disease Preclinical Data
Zai Lab presents promising preclinical data for ZL-1503, an IL-13/IL-31Rα bispecific antibody targeting rapid itch relief and inflammation reduction in atopic diseases.